Memphasys Limited (ASX:MEM) has entered its first commercial agreement in New Zealand for its Felix sperm preparation technology, signing a two-year supply arrangement with Health New Zealand | Te Whatu Ora to serve Fertility Plus, a government-operated IVF clinic located at Auckland's Greenlane Clinical Centre.

Key Points

  • Two-year agreement with Health New Zealand | Te Whatu Ora commencing 1 November 2026, with a further 24-month renewal period available to Health NZ
  • Minimum purchase volume of 1,200 Felix cartridges contracted over the initial term, with rollover provisions for any unmet volume
  • Initial delivery of 500 cartridges and one Felix console scheduled within 30 days of agreement execution, followed by quarterly deliveries
  • Agreement is non-exclusive and subject to contractual termination provisions; commercial unit pricing has not been disclosed

Agreement Terms and Initial Delivery Schedule

The agreement has an initial two-year term commencing 1 November 2026, specifying a minimum purchase volume of 1,200 Felix cartridges, subject to rollover provisions for any unmet volume. The initial delivery comprises 500 cartridges and one Felix console, scheduled within 30 days of agreement execution. Subsequent deliveries are to follow on a scheduled quarterly basis, with the option for additional orders to be placed. Commercial unit pricing has not been disclosed. The agreement is non-exclusive and subject to its contractual termination provisions.

Fertility Plus Supply and Australia–New Zealand Commercial Strategy

Under the agreement, Felix will be supplied to Fertility Plus, a government-operated IVF clinic at Auckland's Greenlane Clinical Centre. According to the filing, Memphasys is focused on establishing a direct-to-clinic presence across its home markets of Australia and New Zealand, with the stated objective of maximising market penetration, protecting margins, and strengthening customer relationships. The company said this approach is designed to deliver clinical and technical support and complements its international distribution strategy and other strategic partnerships.

International Commercial Footprint Across Multiple Regions

The New Zealand agreement follows commercial arrangements the company has previously disclosed across Europe, Australia, Asia, and the Middle East. Marjan Mikel, Chair of the Memphasys Commercialisation Committee, stated that securing an agreement with Health New Zealand for a publicly operated IVF clinic reinforces the global appeal of Felix. Mikel added that the commitment to purchase 1,200 cartridges provides a foundation in New Zealand, and that the Felix value proposition continues to resonate across markets, strengthening confidence in growing recurring cartridge revenues. The company said it remains focused on growing its IVF clinic installed base and converting adoption into repeat cartridge purchases.